Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLCTony Mok, Gilberto Lopes, Iveta Kudaba et al.|Annals of Oncology|2019Cited by 39